Access Bio, Inc. (KOSDAQ:950130)
South Korea · Delayed Price · Currency is KRW 3,390.00
-160.00 (-4.51%)
May 21, 2026, 3:30 PM KST
Access Bio Revenue
In the year 2025, Access Bio had annual revenue of 31.26B KRW, down -72.21%. Access Bio had revenue of 5.23B in the quarter ending December 31, 2025, a decrease of -81.74%.
Revenue
31.26B
Revenue Growth
-72.21%
P/S Ratio
4.00
Revenue / Employee
309.46M
Employees
n/a
Market Cap
124.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.26B | -81.21B | -72.21% |
| Dec 31, 2024 | 112.46B | -236.18B | -67.74% |
| Dec 31, 2023 | 348.64B | -685.22B | -66.28% |
| Dec 31, 2022 | 1.03T | 528.75B | 104.68% |
| Dec 31, 2021 | 505.11B | 383.31B | 314.71% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.81T |
| Celltrion | 4.16T |
| Samsung Epis Holdings | 1.51T |
| Jeil Pharma Holdings | 657.61B |
| HANDOK | 535.14B |
| ALTEOGEN | 215.86B |
| DRTECH | 116.30B |
| Shinhung | 102.61B |